<code id='87B1262D52'></code><style id='87B1262D52'></style>
    • <acronym id='87B1262D52'></acronym>
      <center id='87B1262D52'><center id='87B1262D52'><tfoot id='87B1262D52'></tfoot></center><abbr id='87B1262D52'><dir id='87B1262D52'><tfoot id='87B1262D52'></tfoot><noframes id='87B1262D52'>

    • <optgroup id='87B1262D52'><strike id='87B1262D52'><sup id='87B1262D52'></sup></strike><code id='87B1262D52'></code></optgroup>
        1. <b id='87B1262D52'><label id='87B1262D52'><select id='87B1262D52'><dt id='87B1262D52'><span id='87B1262D52'></span></dt></select></label></b><u id='87B1262D52'></u>
          <i id='87B1262D52'><strike id='87B1262D52'><tt id='87B1262D52'><pre id='87B1262D52'></pre></tt></strike></i>

          
          WSS
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia